A beloved company that has been part of the fabric of the US and has served hundreds of millions of customers around the ...

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

Dr. Philip A. Chan joined GoLocal to discuss the new wave of weight loss drugs and their implications for fighting obesity as well as their implications for other applications like kidney disease and ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

The trade threats could reduce exports to the United States and dampen investment in Europe, dealing a blow to growth at a ...

Last year was a pivotal year for the pharmaceutical industry. Under the IRA’s Medicare Drug Price Negotiation Program (the ...

The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.